These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34563457)

  • 1. Addition of plerixafor for mobilization of stem cells with bortezomib is feasible in dialysis-dependent multiple myeloma.
    Taenaka R; Takigawa K; Okamura K; Obara T; Nishimura N; Kohno K; Aoki K; Ogawa R
    Transfus Apher Sci; 2021 Dec; 60(6):103279. PubMed ID: 34563457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients.
    Bekadja MA; Mansour B; Ouldjeriouat H; Entasoltan B; Bouchama S; Charef L; Amani K; Hakiki N; Bouamama F; Osmani S; Brahimi M; Arabi A; Bouhass R; Yafour N
    Transfus Apher Sci; 2021 Jun; 60(3):103070. PubMed ID: 33612450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient.
    Prakash VS; Malik PS; Sahoo RK; Pramanik R; Choudhary P; Varshney AN; Kumar L
    Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):44-51. PubMed ID: 34452863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Español de Trasplante Hematopoyético (GETH).
    Cid J; Monsalvo S; Castillo C; Pascual C; Moreno-Jiménez G; López-Parra M; Andón C; Guerra L; Esquirol A; Sánchez-Ortega I; Ortega S; Zalba S; Martínez C; Rovira M; Marín P; Lozano M;
    Transfus Apher Sci; 2021 Apr; 60(2):103052. PubMed ID: 33483284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
    Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
    Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience.
    Malinowska I; Romiszewski M; Smalisz K; Stelmaszczyk-Emmel A; Nasilowska-Adamska B; Krol M; Urbanowska E; Brozyna A; Baginska-Dembowska B
    Transfus Apher Sci; 2021 Jun; 60(3):103077. PubMed ID: 33583716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with Plerixafor: A retrospective, multicenter study of a large series of patients.
    Antelo ML; Altuna A; Gimeno JJ; Ferreiro JJ; Amunárriz C; Mateos JJ; Zalba S; Alkorta A; Rifón J; Arroyo JL; Uresandi A; Moreno JA; Nájera MJ; Pinzón S; García A; Vallejo JC;
    Transfus Apher Sci; 2021 Jun; 60(3):103130. PubMed ID: 33840626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
    Fergadis E; Assi A; Kranidioti E; Kosma A; Karakosta M; Miltiadous C; Dimitriadis GK; Grivas A; Athanasopoulos A; Lianos E; Kosmas C
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e50-e57. PubMed ID: 31884151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
    Yang C; Dehghani M; Hopman W; Bhella S
    J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful "on-demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors.
    Corbingi A; Metafuni E; Di Salvatore M; Putzulu R; Chiusolo P; Schinzari G; Massini G; Rossi E; Zini G; Cassano A; Sica S; Piccirillo N
    J Clin Apher; 2022 Feb; 37(1):65-69. PubMed ID: 34822725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
    Okubo M; Furuta Y; Nakamura Y; Osawa T; Tada N; Sawada T; Yamatoya K; Sekiguchi Y; Araki Y; Miyake K; Noguchi M; Komatsu N; Ohsaka A
    Ther Apher Dial; 2021 Oct; 25(5):687-696. PubMed ID: 33325621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection.
    Gupta GK; Perreault S; Seropian SE; Tormey CA; Hendrickson JE
    Transfus Apher Sci; 2021 Jun; 60(3):103069. PubMed ID: 33546988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
    Rybinski B; Rapoport AP; Badros AZ; Hardy N; Kocoglu M
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e716-e729. PubMed ID: 35504807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
    J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
    He X; Jiang D; Zhao L; Chen S; Zhu Y; He Q; He Y
    Cancer Med; 2024 Jun; 13(11):e7356. PubMed ID: 38850125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.
    Gregory KM; Rao KV; Armistead PM
    Ann Pharmacother; 2010 Dec; 44(12):2028-30. PubMed ID: 21098756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.
    Ri M; Matsue K; Sunami K; Shimazaki C; Hayashi A; Sunaga Y; Sasaki T; Suzuki K
    Int J Hematol; 2017 Oct; 106(4):562-572. PubMed ID: 28527129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
    Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEdical Database AnaLysIS of Japanese multiple myeloma patienTs with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantation.
    Iida S; Ishida T; Miyamoto T; Teramukai S; Shirai H; Kanamori R; Tajima Y; Crawford B; Yi J; Teshima T
    Int J Hematol; 2022 Sep; 116(3):411-422. PubMed ID: 35551631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.